AstraZeneca Gets Broader Approval for Heart Failure Treatment in US
By Christian Moess Laursen
AstraZeneca said Tuesday that its Farxiga treatment has been approved in the U.S for use on patients with heart failure.
The Anglo-Swedish pharma giant said Farxiga was previously approved in the U.S. for adults with heart failure with reduced ejection fraction.
The approval by the Food and Drug Administration was based on positive results from a trial evaluating the efficacy of Farxiga, the company said.
Write to Christian Moess Laursen at christian.moess@wsj.com
(END) Dow Jones Newswires
May 09, 2023 02:31 ET (06:31 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Going Into Earnings, Is Microsoft a Buy, a Sell, or Fairly Valued?
-
Big Banks: High Interest Rates and Sticky Inflation Haven’t Dented Consumer Spending
-
Is the World Deglobalizing?
-
How to Position Your Investment Portfolio Before the 2024 Election
-
Q2 Update: 2024 Outlook for the Stock Market and Economy
-
6 Stocks to Sell and 6 Stocks to Buy Instead
-
Markets Brief: Will the New Inflation Story Hurt Stocks?
-
Magnificent No More? Apple and Tesla Stocks Are Weighing on the Market
-
KeyCorp Earnings: 2024 Net Interest Income Outlook Unchanged; Fees Strong and Expenses Stable
-
Lithium Americas: Shares Plunge on Equity Issuance
-
4 Undervalued Semiconductor Stocks
-
Comerica Earnings: Net Interest Income and Expense Outlook Steady
-
Kinder Morgan Earnings: AI Growth Likely to Add Second Leg to Gas Demand on Top of US LNG Exports
-
Going Into Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
United Airlines Earnings: Strong Revenue Offset by Ongoing Investments
-
19 Best Healthcare Companies to Invest In